A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: A double-blind, placebo-controlled, multicenter study

Pediatric Drugs

Volumn 9, Issue SUPPL. 1, 2007, Pages 21-31

  Chuchalin, Alexander ^a   Csiszér, Eszter ^b   Gyurkovics, Kàlmàn ^c   Bartnicka, Maria Trawińska ^d   Sands, Dorota ^e   Kapranov, Nikolai ^f   Varoli, Guido ^g   Preti, Pier Alessandro Monici ^g   Mazurek, Henryk ^h  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b National Institute of Pulmonology   (Hungary)

^c Pulmonology Hospital   (Hungary)

^d Cystic Fibrosis Center   (Poland)

^e INSTITUTE OF MOTHER AND CHILD   (Poland)

^f RESEARCH CENTRE FOR MEDICAL GENETICS   (Russian Federation)

^g CHIESI FARMACEUTICI S P A   (Italy)

^h Bronchiology and Cystic Fibrosis   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

TOBRAMYCIN;

ADOLESCENT; ADULT; AEROSOL; ARTICLE; AUDIOMETRY; BACTERIUM CULTURE; BODY MASS; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HEMOPTYSIS; HOSPITALIZATION; HUMAN; INFECTION SENSITIVITY; KIDNEY FUNCTION; LUNG FUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NEBULIZATION; NEBULIZER; NUTRITIONAL STATUS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SPUTUM; STATISTICAL SIGNIFICANCE; SUPERINFECTION; TINNITUS; TREATMENT DURATION; TREATMENT OUTCOME; VOICE CHANGE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AEROSOLS; ANTI-BACTERIAL AGENTS; CHILD; CHRONIC DISEASE; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 34249945743     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709001-00004     Document Type: Article

References (33)

1. Smith AL. Inhaled antibiotic therapy. What drug? What dose? What regimen? What formulation? J Cystic Fibrosis 2002; 1: S189-93
2. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003; 361: 681-9
3. Ballmann M, Rabsch P, von der Hardt H. Long term follow-up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 1998 Sep; 53 (9): 732-7
4. Farrel PM, Shen G, Spolaingard M, et al. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics 1997; 100 Suppl. 2: 1-9
5. Moss RB. Administration of aerosolised antibiotics in cystic fibrosis. Chest 2001; 120: 107-113S
6. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23-30
7. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20: 658-64
8. Poli G, Acerbi D, Pennini R, et al. Clinical pharmacology study of Bramitob®, a tobramycin solution for nebulization, in comparison with Tobi®. Pediatr Drugs 2007; 9 Suppl. 1: 3-9
9. Nikolaizik WH, Trociewicz K, Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J 2002; 20: 122-6
10. Lenoir G, Antypkin YG, Miano A, et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Drugs 2007; 9 Suppl. 1: 11-20
11. Johansen HK, Hoiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 1992; 47: 109-11
12. Quanjer PhH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Eur Respir J 1993; 6 Suppl. 16: 5-40
13. Knudson RJ, Lebowitz MD, Holberg CJ. Changes in the normal maximal respiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127: 725-34
14. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 13th information supplement. M100-S13. Wayne (PA): NCCLS, 2003
15. Henry DA, Campbell ME, LiPuma JJ, et al. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol 1997; 35 (3): 614-9
16. Bavenfein A, Rotter K, Weisslein-Pfister C. Selective procedure to isolate Haemophilus influenzae from sputa with large quantities of Pseudomonas aeruginosa. Infection 1987; 15: 64-7
17. Hodson ME. Treatment of cystic fibrosis in the adult. Respiration 2000; 67 (6): 595-607
18. Lewis JA, Jones DR, Rohmel J. Biostatistical methodology in clinical trials: European guideline. Stat Med 1995; 14: 1655-82
19. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326: 1187-91
20. Gibson RL, Burns JL, Mamsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-51
21. Corey M, McLaughlin FJ, Williams M, et al. A comparison of survival growth and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988; 41: 583-91
22. Bell SC, Bowermann AR, Davies CA, et al. Nutrition in adults with cystic fibrosis. Clin Nutr 1998; 17: 211-5
23. Wiedemann B, Paul KD, Stern M, et al. Evaluation of body mass index percentiles for assessment of malnutrition in children with cystic fibrosis. Eur J Clin Nutr. Epub 2007 Jan 10
24. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121: 55-63
25. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 2007 Feb; 19 (1): 83-8
26. Taccetti G, Campana S, Festini F, et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26: 458-61
27. Jones AM. Eradication therapy for early Pseudomonas infection in CF: many questions still unanswered. Eur Respir J 2005; 26: 373-5
28. Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125: 1-39S
29. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179: 1190-6
30. Nikolaizik WH, Jenni-Galovic V, Schoni M. Bronchial constriction after nebulised tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Eur J Pediatr 1995; 155: 608-11
31. Ramagopal M, Lands LC. Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis. Pediatr Pulmonol 2000; 29: 366-70
32. Nikolaizik WH, Trociewicz K, Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J 2002; 20: 122-6
33. Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol 2006; 31: 846-58